KCTD5P1: A Drug Target / Disease Biomarker (G100422094)

Target Name: KCTD5P1

NCBI ID: G100422094

KCTD5P1

Other Name(s): LOC100422094 | KCTD5 pseudogene 1 | Potassium channel tetramerization domain containing 5 pseudogene

KCTD5P1: A Drug Target / Disease Biomarker

KCTD5P1, also known as KCTD5 or K-type chloride channel subfamily D member 5, is a protein that is expressed in various tissues throughout the body. It is a key component of the nervous system and plays a crucial role in the regulation of ion channels and neurotransmitter release. KCTD5P1 has been identified as a potential drug target and has been shown to modulate a wide range of physiological processes, including pain perception, anxiety, and depression.

KCTD5P1 is a transmembrane protein that is expressed in the brain, spinal cord, and peripheral tissues. It is a member of the K-type chloride channel subfamily, which is a family of voltage-dependent ion channels that play a central role in the regulation of neurotransmitter release and other physiological processes. The KCTD5P1 gene is located on chromosome 6 and has been shown to encode a protein that is similar to other members of the K-type chloride channel subfamily.

KCTD5P1 has been shown to play a role in the regulation of a wide range of physiological processes, including pain perception, anxiety, and depression. For example, studies have shown that KCTD5P1 is involved in the regulation of pain sensitivity and that it is a potential drug target for pain relief.

In addition to its role in pain perception, KCTD5P1 has also been shown to be involved in the regulation of anxiety and depression. Studies have shown that KCTD5P1 is involved in the regulation of neurotransmitter release from the brain and that it is a potential target for antidepressants. Additionally, KCTD5P1 has been shown to be involved in the regulation of pain sensitivity and anxiety in stress-induced animals, suggesting that it may play a role in the regulation of stress-induced anxiety and depression.

KCTD5P1 has also been shown to play a role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. Studies have shown that KCTD5P1 is involved in the regulation of synaptic plasticity and that it may play a role in the development of neurodegenerative diseases.

In addition to its role in pain perception, anxiety, and synaptic plasticity, KCTD5P1 has also been shown to play a role in the regulation of other physiological processes, including cardiovascular function and neuroendocrine regulation.

KCTD5P1 is a potential drug target because of its involvement in the regulation of a wide range of physiological processes and its role in the development of neurodegenerative diseases. Studies have shown that blocking KCTD5P1 with small molecule inhibitors has potential therapeutic benefits in a variety of neuropsychiatric conditions, including pain perception, anxiety, and depression. Additionally, KCTD5P1 has been shown to be involved in the regulation of synaptic plasticity and may be a potential target for neuroplasticity-based therapies. Further research is needed to fully understand the role of KCTD5P1 in neurotransmission and to develop effective therapies based on this protein.

Protein Name: KCTD5 Pseudogene 1

The "KCTD5P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD5P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets